TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

Abstract Objective Relapsed epithelial ovarian cancer (EOC) is frequently treated with pegylated liposomal doxorubicin (PLD). Unfortunately, most patients do not benefit from treatment. Prediction of response is crucial to optimize PLD use and avoid unnecessary toxicities. We aimed at assessing the...

Full description

Bibliographic Details
Main Authors: Eleonora Ghisoni, Furio Maggiorotto, Fulvio Borella, Gloria Mittica, Sofia Genta, Gaia Giannone, Dionyssios Katsaros, Alberto Sciarrillo, Annamaria Ferrero, Ivana Sarotto, Jessica Erriquez, Maria Flavia Di Renzo, Massimo Aglietta, Giorgio Valabrega
Format: Article
Language:English
Published: BMC 2019-02-01
Series:Journal of Ovarian Research
Subjects:
Ovarian cancer
Topoisomerase 2 alpha
Pegylated liposomal doxorubicin
Online Access:http://link.springer.com/article/10.1186/s13048-019-0492-6

Internet

http://link.springer.com/article/10.1186/s13048-019-0492-6

Similar Items